On February 2, 2023 Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, reported the company will host a conference call and live webcast on Thursday, February 23, 2023, at 8:00 a.m. ET to report its fourth quarter and year end 2022 financial results and other business highlights (Press release, Agios Pharmaceuticals, FEB 2, 2023, https://investor.agios.com/news-releases/news-release-details/agios-webcast-conference-call-fourth-quarter-and-year-end-2022 [SID1234626756]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast can be accessed under "Events & Presentations" in the Investors section of the company’s website at www.agios.com. The webcast will be archived and made available for replay on the company’s website beginning approximately two hours after the event.

On February 2, 2023 CTI BioPharma Corp. (Nasdaq: CTIC) reported that senior leadership will participate in a Fireside Chat at the following investor conferences in February 2023 (Press release, CTI BioPharma, FEB 2, 2023, View Source [SID1234626737]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Partners 5th Annual Oncology Conference
Wednesday, February 8, 2023
10:45 a.m. ET
New York, NY

SVB Securities Global Biopharma Conference
Wednesday, February 15, 2023
3:40 p.m. ET
Virtual

The presentations will be webcast live and available for replay from the Investors section of CTI BioPharma’s website at www.ctibiopharma.com.

On February 2, 2023 POINT Biopharma Global Inc. (NASDAQ: PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, reported management will participate in the following upcoming investor conferences (Press release, Point Biopharma, FEB 2, 2023, View Source [SID1234626736]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim 5th Annual Oncology Conference

Format: Fireside Chat and 1×1 Meetings

Location: New York, NY

Date: Wednesday, February 8, 2023

Time: 2:10 pm ET

‍
SVB Securities Global Biopharma Conference

Format: Fireside Chat and 1×1 Meetings

Location: Virtual

Date: Thursday, February 16, 2023

Time: 11:20 am ET

‍
Cowen 43rd Annual Health Care Conference

Format: GI/GU Oncology Panel Discussion and 1×1 Meetings

Location: Boston, MA

Date: Tuesday, March 7, 2023

Time: 12:50pm ET

‍
Oppenheimer 33rd Annual Healthcare Investor Conference

Format: Fireside Chat and 1×1 Meetings

Location: Virtual

Date: Monday, March 13, 2023

Time: 8:40am ET

‍
2023 Bloom Burton & Co. Healthcare Investor Conference

Format: Presentation and 1×1 Meetings

Location: Toronto, ON

Dates: Tuesday, April 25 and Wednesday, April 26, 2023

‍

On February 2, 2023 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, reported that company management will participate in a fireside chat and one-on-one investor meetings during the SVB Securities Global Biopharma Conference, which is taking place virtually from February 14 – 16, 2023 (Press release, AC Immune, FEB 2, 2023, View Source [SID1234626735]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the fireside chat, AC Immune’s CEO Dr. Andrea Pfeifer will provide an overview of the company’s precision medicine approach and pipeline, which includes 16 therapeutic and diagnostic programs collectively designed to shift the neurodegenerative disease treatment paradigm towards earlier diagnosis and disease prevention. Dr. Pfeifer will also discuss the company’s wholly-owned anti-amyloid beta vaccine, ACI-24.060, which recently showed positive initial interim safety and immunogenicity in patients with Alzheimer’s disease in the Phase 1b/2 ABATE trial.

The fireside chat will take place on February 14, 2023, at 8:40 AM ET / 2:40 PM CET. A webcast of the fireside chat will be available on the Events Page of AC Immune’s website. Following the fireside chat, a replay will be archived in the same location.

On February 2, 2023 PharmaCyte Biotech, Inc. (Nasdaq:PMCB) ("PharmaCyte" or the "Company"), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box for potential development of cellular therapies for cancer, diabetes and malignant ascites, reported that its Board of Directors has authorized a second share repurchase program to repurchase up to $10 million of PharmaCyte’s outstanding common stock (Press release, PharmaCyte Biotech, FEB 2, 2023, View Source [SID1234626734]). This second share repurchase authorization is effective immediately for a two-year period. PharmaCyte expects to fund the program with its available cash. The Company enacted a similar program in June 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PharmaCyte’s CEO Josh Silverman commented, "Based on our continued and very fortunate cash position, we believe it is essential that we continue to create additional shareholder value wherever and whenever possible. We believe this follow-on stock buyback program is an essential part of these activities and believe that it demonstrates our commitment to our shareholder base. To that end, we also continue to prudently manage our expenses to maintain our strong balance sheet. In the meantime, we continue our evaluation of our current programs while actively exploring the potential for other strategic opportunities."

The shares may be repurchased from time to time in open market transactions, privately negotiated block transactions, or other means in accordance with applicable securities laws. The timing of the purchase, the number of shares repurchased, and the prices paid for the shares under the program will depend on general business and market conditions, the trading price of PharmaCyte’s common stock and corporate and regulatory limitations. The share repurchase program does not obligate PharmaCyte to acquire a specific dollar amount or number of shares and may be extended, modified, or discontinued at any time.